Evaluation of commercial SARS-CoV-2 serological assays in Canadian public health laboratories.
Antibodies
COVID-19
SARS-CoV-2
Sero-surveillance
Serology
Journal
Diagnostic microbiology and infectious disease
ISSN: 1879-0070
Titre abrégé: Diagn Microbiol Infect Dis
Pays: United States
ID NLM: 8305899
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
30
09
2020
revised:
12
04
2021
accepted:
18
04
2021
pubmed:
24
8
2021
medline:
14
10
2021
entrez:
23
8
2021
Statut:
ppublish
Résumé
The COVID-19 pandemic has led to the influx of immunoassays for the detection of antibodies towards severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into the global market. The Canadian Public Health Laboratory Network Serology Task Force undertook a nationwide evaluation of twelve laboratory and 6 point-of-care based commercial serological assays for the detection of SARS-CoV-2 antibodies. We determined that there was considerable variability in the performance of individual tests and that an orthogonal testing algorithm should be prioritized to maximize the accuracy and comparability of results across the country. The manual enzyme immunoassays and point-of-care tests evaluated had lower specificity and increased coefficients of variation compared to automated enzyme immunoassays platforms putting into question their utility for large-scale sero-surveillance. Overall, the data presented here provide a comprehensive approach for applying accurate serological assays for longitudinal sero-surveillance and vaccine trials while informing Canadian public health policy.
Identifiants
pubmed: 34425450
pii: S0732-8893(21)00105-X
doi: 10.1016/j.diagmicrobio.2021.115412
pmc: PMC8377389
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
115412Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare no competing interests.
Références
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32513859
J Clin Microbiol. 2020 Sep 22;58(10):
pubmed: 32665420
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32350047
J Clin Microbiol. 2004 Nov;42(11):5309-14
pubmed: 15528730
Thorax. 2020 Dec;75(12):1082-1088
pubmed: 32796119
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
CMAJ. 2020 Jun 8;192(23):E632-E633
pubmed: 32409521
Cell Rep Med. 2020 Oct 20;1(7):100126
pubmed: 33015650
J Clin Microbiol. 2020 Aug 24;58(9):
pubmed: 32580948
J Med Virol. 2021 Jan;93(1):424-433
pubmed: 32584487
J Clin Virol. 2020 Jul;128:104433
pubmed: 32405254
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Sci Immunol. 2020 May 19;5(47):
pubmed: 32430309